Different tumor microbiomes in esophageal cancer patients directly impact survival rates.

• Patients with esophagotype A have 3-year overall survival rates of 73%, versus 57% for esophagotype B (p < 0.05).
• Recurrence-free survival is also better in esophagotype A at 80.7%, compared to 64% in esophagotype B.

Understanding these microbiome signatures can help tailor treatment strategies for better patient outcomes.

• Microbial clustering is an independent prognostic factor, highlighting potential for personalized therapies.